On 24 September, uniQure announced positive topline results from its pivotal Phase I/II studies (HD-GENE-TRX1, HD-GENE-TRX2) ...

Bayer vice president Luiz Barberini explains how the German giant’s cooperation with suppliers fosters long-term trial ...

As China's biotech sector continues to buzz with innovation, the country is rapidly integrating into the global clinical ...

MediciNova has completed full patient enrolment in the COMBAT-ALS Phase IIb/III clinical trial of MN-166 (ibudilast) as a ...

PepGen’s stock has risen by over 120% after its investigational myotonic DM1 candidate reported the highest mean splicing correction in a Phase I trial.

In a pair of Phase III trials, J&J and Protagonists' icotrokinra beat BMS' Sotyktu on every skin-clearness measure.

AstraZeneca’s Saphnelo (SC) administration has shown a decrease in disease activity in individuals with systemic lupus ...

Belite Bio has concluded the final participant visit in its Phase III DRAGON study, which is focused on assessing the ...

Datavant has partnered with life sciences commercialisation firm Indegene to enhance recruitment of subjects for clinical ...

Kairos Pharma has reported encouraging interim efficacy data from its Phase II study of ENV105 in individuals with mCRPC.

REDCap Cloud (nPhase) has introduced a new platform to unify real-world evidence with clinical study data within a single ...

Nektar Therapeutics has presented data of its atopic dermatitis (AD) candidate rezpeg (rezpegaldesleukin), which sent the ...